Case report reveals dupilumab improves symptoms in children with harlequin ichthyosis, suggesting a new treatment option.
Harlequin ichthyosis (HI) is a rare epidermal differentiation disorder characterized by thick hyperkeratotic plates, fissuring, and high neonatal morbidity. Long‐term management remains challenging. We report two children with genetically confirmed HI who demonstrated meaningful improvement in pruritus, erythema, scaling, and overall well‐being following dupilumab therapy, suggesting a potential role for IL‐4/IL‐13 blockade as an adjunct or alternative treatment in HI.
No takes yet. Share an insight, caveat, or question.
Chiramel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: